- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Novavax begins phase 2 portion of COVID-19 vaccine trial | ||
| Di | Takeda to sell Japan consumer health unit for $2.3bn | ||
| Di | WHO says 172 countries are poised to participate in COVID-19 vaccine initiative | ||
| Di | EU concludes discussions with Moderna for COVID-19 vaccine | ||
| Mo | COVID-19 vaccine 'unlikely' to be available this year, says UK's chief medical officer | ||
| Mo | Vertex's triple combination CF therapy to become available on the NHS | ||
| Mo | FDA grants emergency approval for blood plasma treatments for COVID-19 | ||
| Mo | Audentes' rare disease gene therapy programme indefinitely delayed after third patient death | ||
| Mo | We need to keep learning to keep innovating | ||
| Fr | Pifzer, BioNTech eye October approval for mRNA-based COVID-19 vaccine | ||
| Fr | Novartis wins FDA approval for relapsing MS drug Kesimpta | ||
| Fr | Janssen scores another expansion for new Darzalex combination in the US | ||
| Fr | Keytruda improves survival in first-line oesophageal cancer | ||
| Fr | Trust - years to build, seconds to break and forever to repair | ||
| Do | J&J inks $6.5bn all-cash deal to acquire Momenta | ||
| Do | US payments for COVID-19 vaccines tied to specific timing milestones | ||
| Do | NICE recommends Roche's Polivy for B-cell lymphoma | ||
| Do | Roche, Regeneron partner on COVID-19 antibody cocktail | ||
| 19.08. | Matt Hancock unveils new National Institute for Health Protection | ||
| 19.08. | Vaccine nationalism must be prevented, says WHO director-general | ||
| 19.08. | Britain ramps up COVID-19 testing to track spread of infections | ||
| 19.08. | GSK doses first patients in phase 3 meningitis vaccine trial | ||
| 19.08. | Evoke KYNE promotes Dante DelVecchio to senior VP | ||
| 18.08. | BMS pays $475m for Dragonfly's IL-12 immunotherapy programme | ||
| 18.08. | AZ scores FDA priority review for new Imfinzi fixed-dose regimen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
